Gene Editing Market Size Worth USD 35.84 Billion in 2032 | Emergen Research

Rising demand for synthetic genes in both developed and developing countries are major factors driving Gene Editing Gene Editing Market revenue growth

Vancouver, Nov. 30, 2023 (GLOBE NEWSWIRE) — The global gene editing market size was USD 6.11 Billion in 2021 and is expected to register a revenue CAGR of 17.5% during the forecast period. The global gene editing market is experiencing significant growth, driven by advancements in technology and a surge in research and development activities. Gene editing, also known as genome editing, involves the precise alteration of an organism’s DNA, enabling the addition, removal, or modification of genetic material. The market is witnessing a remarkable shift with the CRISPR/Cas9 segment dominating the landscape, and applications ranging from diagnostics to drug discovery and development.
Technological Advancements Propel CRISPR/Cas9 Segment to the Forefront

In 2021, the CRISPR/Cas9 segment claimed the largest revenue share in the global gene editing market. This dominance is attributed to the superiority of CRISPR/Cas9 over other genome editing techniques in terms of speed, cost, accuracy, and efficiency. CRISPR/Cas9 is a versatile tool with vast potential for treating diseases with a genetic component, including cancer, hepatitis B, and high cholesterol. The technology is not limited to healthcare but extends to industries such as agriculture, where efforts are underway to address challenges like the shortage of human organs available for transplant procedures.

Applications Driving Market Growth

The cell line segment secured the largest revenue share in 2021, emphasizing the integration of DNA technology with cell technology. Researchers are leveraging gene editing technologies to enhance the production of biotherapeutic proteins, improving bioactivity and product quality attributes. Additionally, the drug discovery and development segment maintained a steady revenue share, with CRISPR gene editing playing a crucial role in assessing potential treatment targets and offering new perspectives for various diseases.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/132

End-use Landscape: Pharmaceutical and Biotech Companies Lead the Way

Pharmaceutical and biotech companies accounted for the largest revenue share in 2021, driven by increasing research efforts for the discovery of innovative therapeutics. Major players in the market are strategically partnering to advance gene editing technologies. For example, CANbridge Pharmaceuticals and LogicBio Therapeutics announced a strategic partnership to develop gene editing technology for the treatment of rare and serious diseases.

Academic Institutions and Research Centers Play a Vital Role

While the pharmaceutical and biotech companies segment leads, academic institutions and research centers contribute significantly to the gene editing market, with a steady revenue share. The technology’s adoption in university-based campuses is on the rise, with institutes incorporating teaching modules to raise awareness and understanding of gene editing technologies among students.

Regional Insights: North America Takes the Lead

North America claimed the largest revenue share in 2021, driven by the greater adoption of advanced gene editing techniques and an increase in chronic diseases. The U.S. market, in particular, saw substantial funding for gene editing research, with collaborations between companies like Vertex Pharmaceuticals and CRISPR Therapeutics driving further developments. In Europe, steady revenue growth was observed, propelled by an expansion of life science research and increased spending on research and development. The UK market led the way, implementing new regulations to facilitate the adoption of gene editing technologies. In the Asia Pacific region, Japan took the lead in gene editing research, with the introduction of genome-edited tomatoes through CRISPR-Cas9 technology.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/132

Scope of Research

MAJOR COMPANIES and Market Share Analysis

The global gene editing market is fairly fragmented, with many large and medium-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, and introducing more effective genome editing technologies. Some major players included in the global gene editing market report are:

• Intellia Therapeutics, Inc.
• Beam Therapeutics
• Verve Therapeutics, Inc.
• Sana Biotechnology
• Editas Medicine
• Precision BioSciences
• CRISPR Therapeutics
• Thermo Fisher Scientific
• Inscripta, Inc.
• Spark Therapeutics, Inc.

Strategic Development

• On 20 November 2020, Eli Lilly and Company and Precision BioSciences, Inc. announced a research partnership and exclusive license agreement to use Precision’s proprietary ARCUS genome editing platform for investigation and development of potential in vivo treatments for genetic disorders, with a preliminary focus on Duchenne Muscular Dystrophy (DMD) and two other undisclosed gene targets. ARCUS is a distinct, proprietary, and flexible genome editing platform with characteristics including specificity, versatility in efficient edits (knock-in, knock-out, and repair), and compact size, enabling a variety of therapeutic editing. I-CreI, a homing endonuclease with controllable potency and selectivity, is a naturally occurring genome-editing enzyme that serves as the basis for this platform.
• On 18 April 2022, Thermo Fisher Scientific introduced a new GMP-manufactured Gibco CTS TrueCut Cas9 Protein, as high-quality auxiliary materials and documentation are essential, as researchers using genome editing techniques transition from basic research to therapeutic settings. Gibco CTS TrueCut Cas9 Protein is an attractive option for CAR T-cell therapy research employing CRISPR-Cas9 genome editing since it consistently achieves high editing efficiency in all studied cell lines and better than 90% efficiency in human primary T-cells.

Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/132

Segments Covered in Report

For the purpose of this report, Emergen Research has segmented the global gene editing market based on technology, application, end-use, and region:

• Technology Outlook (Revenue, USD Billion; 2019-2030)
  • CRISPR/Cas9
  • TALENS
  • ZFN
  • Restriction Enzymes
  • Others
• Application Outlook (Revenue, USD Billion; 2019-2030)
  • Diagnostics
  • Drug Discovery and Development
  • Cell Line
  • Animal and Plant Genetic Engineering
  • Others
• End-use Outlook (Revenue, USD Billion; 2019-2030)
  • Academic Institutions & Research Centers
  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies

• Regional Outlook (Revenue, USD Billion; 2019–2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Benelux
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Turkey
    • Rest of Middle East & Africa

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/gene-editing-market  

Curated Reports You Shouldn’t Miss: Dive In Now!

Facial Treatment Market, By Device (LED Devices, IPL Devices, Laser-based Devices, and Others), By Treatment (Platelet-rich Plasma Therapy, Radiofrequency (RF) Skin Tightening, Microneedling, and Others), By End-use (Beauty Clinics, Dermatology Clinics, and Others), and By Region Forecast to 2030

Dental Care Market Size, Share, Trends, By Product (Toothpastes, Toothbrush & Accessories, Mouthwashes/Rinses, Dental Accessories/Ancillaries), By Application, By Distribution Channel, and By Region Forecast to 2030

Hypercholesterolemia Market, By Disease Type (Genetic and Acquired), By Treatment Type (Statins, Bile-acid Binding Resins, Niacin, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), By Region Forecast to 2030

Negative Pressure Wound Therapy Market, By Product Type (Conventional NPWT, Single-Use NPWT, and Accessories), By Wound Type, By End-Use, and By Region Forecast to 2030

Bio Decontamination Market By Product & Service (Equipment, Services, Consumables), By Agent Type (Hydrogen Peroxide, Chlorine Dioxide, Peracetic Acid, Nitrogen Dioxide), By Type (Chamber, Room), By End-use, By Region, Forecast to 2030

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Explore Our Japanese Version: Gene Editing Market

Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights